Question 1

What is combined oxidative phosphorylation deficiency 55?

Accepted Answer

Combined oxidative phosphorylation deficiency 55 is a multisystem condition that primarily affects energy production within cells. It is associated with pathogenic variants in the POLRMT gene, which plays a key role in mitochondrial transcription. Affected individuals often present in early childhood with a range of developmental and muscular challenges. Although precise prevalence estimates are not available, the condition is considered to be uncommon and exhibits considerable variability in its severity and clinical presentation.

Question 2

What are the symptoms of combined oxidative phosphorylation deficiency 55?

Accepted Answer

The clinical presentation of combined oxidative phosphorylation deficiency 55 is heterogeneous, with notable involvement of the central nervous system as well as muscular and other systemic features. Many affected children experience global developmental delay and intellectual disability, and they may show delayed speech and language development or, in some cases, absent speech. Neurological concerns are often accompanied by myopathy, hypotonia, and muscle weakness, which can manifest as skeletal muscle atrophy and proximal muscle weakness. In addition, physical features such as short stature, microcephaly, and distinct facial characteristics including depressed nasal bridge, anteverted nares, and hypotelorism may be observed. Other findings noted in a subset of individuals include a single transverse palmar crease, bilateral ptosis, and high-frequency hearing impairment, along with laboratory abnormalities such as elevated circulating creatine kinase and lactate levels. That not all individuals experience all features, and severity varies considerably from one person to another.

Question 3

What causes combined oxidative phosphorylation deficiency 55?

Accepted Answer

Combined oxidative phosphorylation deficiency 55 results from pathogenic variants in the POLRMT gene. POLRMT is instrumental in transcribing mitochondrial DNA, and disruptions in its function can impair the energy production processes that many cell types depend upon. The condition has been reported with both autosomal recessive and autosomal dominant patterns of inheritance, meaning that the genetic change may be inherited in different ways. Because the manifestation of symptoms can vary even among family members, genetic counseling is recommended to help families understand the implications for family planning and to discuss recurrence risks. Associated genes include POLRMT.

Question 4

How is combined oxidative phosphorylation deficiency 55 inherited?

Accepted Answer

combined oxidative phosphorylation deficiency 32

MONDO:0054654

RareModerate

combined oxidative phosphorylation deficiency 58

MONDO:0957537

RareModerate

combined oxidative phosphorylation defect type 20

MONDO:0014397

RareModerate

combined oxidative phosphorylation defect type 24

MONDO:0014547

RareModerate

combined oxidative phosphorylation defect type 15

MONDO:0013987

RareModerate

combined oxidative phosphorylation deficiency 45

MONDO:0033533

RareModerate

Question 5

How is combined oxidative phosphorylation deficiency 55 diagnosed?

Accepted Answer

The definitive diagnosis for combined oxidative phosphorylation deficiency 55 is established by molecular genetic testing, which identifies pathogenic variants in the POLRMT gene. In addition to genetic testing, a detailed clinical evaluation that considers the patient’s developmental history, physical examination, and laboratory findings is crucial, especially given the overlap of these features with other conditions. Because many of the clinical features, including developmental delay and myopathic findings, can be seen in other disorders, genetic confirmation is essential to differentiate this condition from others with similar presentations.

Question 6

Are there treatments for combined oxidative phosphorylation deficiency 55?

Accepted Answer

Currently, there are no approved treatments or foundational therapies specifically linked to combined oxidative phosphorylation deficiency 55. As a result, management focuses on supportive care and symptom management tailored to each individual’s needs. This typically involves a multidisciplinary team such as neurologists, developmental pediatricians, and physical therapists to address the varied challenges including developmental delays, muscle weakness, and growth concerns. Regular surveillance is an essential part of long-term care, helping to identify potential complications early and enabling timely interventions. Patients should discuss treatment options with their healthcare team to determine the most appropriate supportive strategies, and genetic counseling is recommended to inform families about inheritance and future family planning.

Question 7

What are the potential complications of combined oxidative phosphorylation deficiency 55?

Accepted Answer

Individuals with combined oxidative phosphorylation deficiency 55 may face various complications due to their condition. These can include ongoing developmental delays, muscle weakness, and growth concerns. Regular monitoring and support from a healthcare team can help identify and manage these complications early, improving overall quality of life.

Question 8

How does combined oxidative phosphorylation deficiency 55 affect daily life for patients and their families?

Accepted Answer

Living with combined oxidative phosphorylation deficiency 55 can present daily challenges for patients and their families. Many affected children may need extra support for developmental delays and muscle weakness, which can impact their ability to participate in typical activities. Families often work with a team of specialists to create tailored support plans that address these unique needs.

Question 9

What is the long-term prognosis for someone with combined oxidative phosphorylation deficiency 55?

Accepted Answer

The long-term outlook for individuals with combined oxidative phosphorylation deficiency 55 varies widely. Some may experience stabilization of their symptoms over time, while others might continue to face significant challenges. With appropriate care and support, many can improve their quality of life and manage complications effectively.

Question 10

What specialists should families consult for managing combined oxidative phosphorylation deficiency 55?

Accepted Answer

Families dealing with combined oxidative phosphorylation deficiency 55 should consider consulting a multidisciplinary team of specialists. This may include neurologists, developmental pediatricians, and physical therapists who can help address the various challenges associated with the condition. Working together, these professionals can provide comprehensive care tailored to the individual needs of the patient.

Research Type	Count	% of Total
Laboratory research	14	58%

Kisho

combined oxidative phosphorylation deficiency 55

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

Recent Publications

combined oxidative phosphorylation deficiency 55

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is combined oxidative phosphorylation deficiency 55?

What are the symptoms of combined oxidative phosphorylation deficiency 55?

What causes combined oxidative phosphorylation deficiency 55?

How is combined oxidative phosphorylation deficiency 55 inherited?

How is combined oxidative phosphorylation deficiency 55 diagnosed?

Are there treatments for combined oxidative phosphorylation deficiency 55?

What are the potential complications of combined oxidative phosphorylation deficiency 55?

How does combined oxidative phosphorylation deficiency 55 affect daily life for patients and their families?

What is the long-term prognosis for someone with combined oxidative phosphorylation deficiency 55?

What specialists should families consult for managing combined oxidative phosphorylation deficiency 55?

Explore clinical features

Recent Publications